Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Biotechnology

Healthcare
$3.95 +2.36%

+$0.09 today

Market cap
$86.45M
Beta
4.47
P/E (TTM)
-1.2
EPS (TTM)
-$3.20
52W Low $3.35High $17.94

Volume 1.32M

Average 0.18M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$54.17M

FY 2025 · Annual

Investing Cash Flow

-$49.67M

FY 2025 · Annual

Financing Cash Flow

$89.25M

FY 2025 · Annual

+8.9% YoY

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.56M)(7.21M)(20.59M)(57.59M)
Depreciation & Amortization110K97K16K(1.31M)
Deferred Income Tax0000
Stock-Based Compensation412K313K439K3.95M
Change in Working Capital(1.31M)(81K)1.57M356K
Accounts Receivables0000
Inventory0000
Accounts Payables31K776K798K239K
Other Working Capital(1.34M)(857K)775K117K
Other Non-Cash Items3.81M1.06M473K421K
Operating Cash Flow(10.54M)(5.82M)(18.09M)(54.17M)
Capital Expenditures00(109K)(95K)
Acquisitions (Net)0000
Purchases of Investments00(11.89M)(129.6M)
Sales of Investments00080.03M
Other Investing Activities(1M)000
Investing Cash Flow(1M)0(12M)(49.67M)
Debt Repayment(1M)000
Common Stock Issued225K0332K89.25M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities1M0(3.34M)0
Financing Cash Flow225K081.99M89.25M
Effect of Forex Changes0000
Net Change in Cash(11.32M)(5.82M)51.91M(14.59M)
Free Cash Flow(10.54M)(5.82M)(18.2M)(54.27M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$57.6M
+ D&A-$1.3M
+ Stock-Based Comp$3.9M
+ Deferred Tax$0
+ Working Capital$356.0K
+ Other Non-Cash$421.0K
= Operating Cash Flow-$54.2M
- Capex-$95.0K
= Free Cash Flow-$54.3M

Analysis

FY2025 free cash flow is -$54.3M. FCF conversion is 94.2% of net income. Operating cash flow was -$54.2M, with capex of -$95.0K. The largest bridge item is Stock-Based Comp at $3.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 8, 2026
8-KCurrent reportOct 8, 2026
3Initial statement of beneficial ownershipOct 8, 2026
4Statement of changes in beneficial ownershipSep 11, 2026
4Statement of changes in beneficial ownershipAug 21, 2026

Does AARD generate free cash flow?

Aardvark Therapeutics, Inc. Common Stock (AARD) generated -$54.27M of free cash flow in fiscal 2025.

How much operating cash flow does AARD produce?

Operating cash flow was -$54.17M, before capital expenditures of $95,000.00.